Clinical Science (1992) 82,273-275 (Printed in Great Britain)
27 3
Enhanced synthesis of neutrophil-activating peptide- I linterleukin-8 in active ulcerative colitis Y. R. MAHIDA, M. CESKA*, F. EFFENBERGER*, L. KURLAK, 1. LINDLEY* and C. J. HAWKEY Department of Therapeutics, University Hospital, Queen’s Medical Centre, Nottingham, U.K., and “Sandoz Forchungsinstitut, Vienna, Austria (Received 4 September 1991; accepted 8 October 1991)
1. We studied neutrophil-activating peptide-l/interleukin-8 in inflammatory bowel disease. 2. Mucosal levels of neutrophil-activating peptide-l/ interleukin-8 were significantly higher in patients with active ulcerative colitis [median 74.5 (range 17.7-450.8) pg/mg] than in patients with active Crohn’s disease I10.4 (4-46.9) pg/mg; P< 0.0021 or in normal control subjects [10.4(4-16.6) pg/mg; P
27 3
Enhanced synthesis of neutrophil-activating peptide- I linterleukin-8 in active ulcerative colitis Y. R. MAHIDA, M. CESKA*, F. EFFENBERGER*, L. KURLAK, 1. LINDLEY* and C. J. HAWKEY Department of Therapeutics, University Hospital, Queen’s Medical Centre, Nottingham, U.K., and “Sandoz Forchungsinstitut, Vienna, Austria (Received 4 September 1991; accepted 8 October 1991)
1. We studied neutrophil-activating peptide-l/interleukin-8 in inflammatory bowel disease. 2. Mucosal levels of neutrophil-activating peptide-l/ interleukin-8 were significantly higher in patients with active ulcerative colitis [median 74.5 (range 17.7-450.8) pg/mg] than in patients with active Crohn’s disease I10.4 (4-46.9) pg/mg; P< 0.0021 or in normal control subjects [10.4(4-16.6) pg/mg; P
